Payment overview · 2025
General Payments
$1,106.30
22 reported records · 6 companies
Healthcare provider profile · identity verified
Stephen Yoelson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TORRINGTON, CT · NPI 1306856463
Verified facts
What the public records show
CMS Open Payments records show Stephen Yoelson, M.D. received $1,106.30 in general payments during 2025 across 22 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $293.20 | 26.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $244.16 | 22.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.96 | 17.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $130.00 | 11.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.99 | 11.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.99 | 11.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,106.30 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $293.20 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $244.16 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $130.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $122.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.78 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 214 |
| Lisinopril | Lisinopril | 779 | 198 |
| Alprazolam | Alprazolam | 502 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 367 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 80 |
| Simvastatin | Simvastatin | 283 | 68 |
| Metformin Hcl | Metformin Hcl | 276 | 72 |
| Furosemide | Furosemide | 251 | 63 |
| Omeprazole | Omeprazole | 233 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 64 |
| Gabapentin | Gabapentin | 221 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 219 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 204 | 30 |
| Losartan Potassium | Losartan Potassium | 201 | 56 |
| Tramadol Hcl | Tramadol Hcl | 181 | 45 |
| Eliquis | Apixaban | 158 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 35 |
| Trazodone Hcl | Trazodone Hcl | 141 | 36 |
| Allopurinol | Allopurinol | 140 | 39 |
| Lorazepam | Lorazepam | 140 | 41 |
| Alendronate Sodium | Alendronate Sodium | 131 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 120 | 22 |
| Prednisone | Prednisone | 119 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 35 |
| Januvia | Sitagliptin Phosphate | 112 | 24 |
| Clonazepam | Clonazepam | 107 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 17 |
| Meloxicam | Meloxicam | 104 | 27 |
| Potassium Chloride | Potassium Chloride | 86 | 23 |
| Ozempic | Semaglutide | 84 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 81 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 21 |
| Sertraline Hcl | Sertraline Hcl | 75 | 19 |
| Jardiance | Empagliflozin | 73 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 13 |
| Mirtazapine | Mirtazapine | 69 | 13 |
| Pregabalin | Pregabalin | 68 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 17 |
| Baclofen | Baclofen | 61 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 18 |
| Ezetimibe | Ezetimibe | 60 | 20 |
| Valsartan | Valsartan | 60 | 16 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 17 |
| Carvedilol | Carvedilol | 53 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 12 |
| Glipizide | Glipizide | 50 | 13 |
| Atenolol | Atenolol | 49 | 16 |
| Diazepam | Diazepam | 49 | suppressed |
| Finasteride | Finasteride | 47 | 15 |
| Spironolactone | Spironolactone | 47 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Linzess | Linaclotide | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 21 |
| Meclizine Hcl | Meclizine Hcl | 38 | 13 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 12 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Nystatin | Nystatin | 34 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 23 |
| Chlorthalidone | Chlorthalidone | 29 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 11 |
| Famotidine | Famotidine | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 11 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Dutasteride | Dutasteride | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,106.30 · 22 records | Bayer Healthcare Pharmaceuticals Inc. | CAPLYTA, JARDIANCE, Kerendia, Ozempic, Rybelsus, UBRELVY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error